Gupta, D. L., Meher, J., Giri, A. K., Shukla, A. K., Mohapatra, E., Ruikar, M. M., & Rao, D. (2024). RBD mutations at the residues K417, E484, N501 reduced immunoreactivity with antisera from vaccinated and COVID-19 recovered patients. Drug Target Insights, 18(1), 20–26. https://doi.org/10.33393/dti.2024.3059